ストックスクリーナーアプリを入手
1.26
0.00%
0.00
前日終値:
$1.26
開ける：
$1.25
24時間の取引高:
404.33K
Relative Volume:
0.48
時価総額：
$136.43M
収益：
$27.08M
当期純損益:
$-37.00M
株価収益率:
-2.4231
EPS:
-0.52
ネットキャッシュフロー:
$-18.46M
1週間 パフォーマンス:
-3.82%
1か月 パフォーマンス:
+5.88%
6か月 パフォーマンス:
-66.84%
1年 パフォーマンス:
+6.78%
1日の値動き範囲:
$1.22
$1.285
1週間の範囲:
$1.22
$1.38
52週間の値動き範囲:
$0.9515
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
ACRS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
1.26 | 141.85M | 27.08M | -37.00M | -18.46M | -0.52 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-18 | 再開されました | Cantor Fitzgerald | Overweight |
| 2024-12-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | アップグレード | BTIG Research | Neutral → Buy |
| 2024-11-19 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-19 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 開始されました | Evercore ISI | Outperform |
| 2022-12-14 | 開始されました | Stifel | Buy |
| 2022-12-01 | 開始されました | Goldman | Buy |
| 2022-10-06 | 開始されました | BTIG Research | Buy |
| 2021-07-23 | 再開されました | Jefferies | Buy |
| 2021-06-15 | 開始されました | Piper Sandler | Overweight |
| 2021-04-21 | 開始されました | H.C. Wainwright | Buy |
| 2019-10-22 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 開始されました | SVB Leerink | Outperform |
| 2018-03-28 | 再開されました | Leerink Partners | Outperform |
| 2018-02-09 | 開始されました | Guggenheim | Buy |
| 2017-06-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 開始されました | Leerink Partners | Outperform |
| 2016-09-30 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-06-10 | 開始されました | Guggenheim | Buy |
| 2015-11-02 | 開始されました | Citigroup | Buy |
| 2015-11-02 | 開始されました | Jefferies | Buy |
すべてを表示
Aclaris Therapeutics Inc (ACRS) 最新ニュース
Common Warts Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma Inc - The Globe and Mail
Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) PT at $10.00 - Defense World
HC Wainwright Has Positive Forecast for ACRS Q3 Earnings - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Holdings Raised by Dimensional Fund Advisors LP - Defense World
Aclaris Therapeutics to Host Virtual Fireside Chat with CEO Neal Walker on May 16, 2025 - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stake Reduced by Price T Rowe Associates Inc. MD - Defense World
Aclaris Therapeutics (ACRS) Price Target Update by HC Wainwright & Co. | ACRS Stock News - GuruFocus
Aclaris Therapeutics (ACRS) Receives Lower Price Target from Ana - GuruFocus
Aclaris Therapeutics Reports Q1 2025 Financial Results - MSN
Androgenetic alopecia Pipeline 2025: Groundbreaking Clinical - openPR.com
Aclaris Therapeutics Reports Q1 2025 Results and Pipeline Updates - MSN
Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer - MSN
Scotiabank Has Lowered Expectations for Aclaris Therapeutics (NASDAQ:ACRS) Stock Price - Defense World
Aclaris Therapeutics (ACRS) Price Target Lowered by Scotiabank | - GuruFocus
Aclaris Therapeutics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Raymond James Financial Inc. Purchases New Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series - GlobeNewswire
Scotiabank Adjusts Price Target for Aclaris Therapeutics (ACRS) - GuruFocus
Aclaris Therapeutics to Participate in the HC Wainwright 'HCW@Home” Series - The Manila Times
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series - GlobeNewswire Inc.
Mariner LLC Sells 10,327 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Aclaris: Q1 Earnings Snapshot - CT Insider
Aclaris Therapeutics Inc earnings beat by $0.02, revenue fell short of estimates - Investing.com India
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Aclaris Therapeutics Reports Q1 2025 Financial Results and Corporate Update with Focus on Immuno-Inflammatory Developments and Extended Cash Runway through 2028 - Nasdaq
Aclaris Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Hims & Hers Has a Superpower in Healthcare - The Globe and Mail
Here's Why I'm Still Buying SoFi Hand Over Fist in 2025 - The Globe and Mail
Aclaris Therapeutics Inc (ACRS)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - DWinneX
Invesco Ltd. Invests $28,000 in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Acquired by JPMorgan Chase & Co. - Defense World
Geode Capital Management LLC Reduces Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
XTX Topco Ltd Acquires New Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 34.8% in April - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Aclaris Therapeutics Names Jesse Hall Chief Medical Officer - marketscreener.com
Aclaris Therapeutics (ACRS) Welcomes Jesse Hall as Chief Medical Officer | ACRS Stock News - GuruFocus
Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer - marketscreener.com
Aclaris Therapeutics appoints new Chief Medical Officer - Investing.com
Aclaris Strengthens Leadership: Humira and Prolia Developer Takes CMO Role to Advance Immunology Pipeline - Stock Titan
Androgenetic Alopecia Treatment Market Generated - openPR.com
Aclaris Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Aclaris Therapeutics Inc (ACRS) 財務データ
収益
当期純利益
現金流量
EPS
17.27%
1.06%
大文字化:
|
ボリューム (24 時間):